Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma

Yunxia Liu, Shuichi Kimpara, Nguyet M. Hoang, Anusara Daenthanasanmak, Yangguang Li, Li Lu, Vu N. Ngo, Paul D. Bates, Longzhen Song, Xiaoyue Gao, Samantha Bebel, Madelyn Chen, Ruoyu Chen, Xiyu Zhang, Paul E. Selberg, Vaishalee P. Kenkre, Thomas A. Waldmann, Christian M. Capitini, Lixin Rui

Blood (2023) 142 (22): 1879–1894.

https://doi.org/10.1182/blood.2023020142

Published: 2023

Includes: Supplemental data

Journal Articles

Minimal Residual Disease (MRD) Testing By Next Generation Sequencing (NGS) after Two Cycles (CY) of Non-Intensive Chemoimmunotherapy Is Predictive of Remission Duration and Need for Maintenance Therapy (MT) in Previously Untreated Mantle Cell Lymphoma (MCL): A Wisconsin Oncology Network Study

Danielle McQuinn, Meredith Hyun, KyungMann Kim, Vaishalee P Kenkre, Christopher D Fletcher, Saurabh A Rajguru, Priyanka A Pophali, Mariah Endres, Mitch Howard, Tim Wassenaar, Ruth Callaway Warren, Ryan J Mattison, Kari B Wisinski, Julie E Chang

Blood (2023) 142 (Supplement 1): 4407.

https://doi.org/10.1182/blood-2023-173871

Published: 2023

Journal Articles

Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities

Blood (2023) 142 (Supplement 1): 2407.

https://doi.org/10.1182/blood-2023-183041

Published: 2023

Journal Articles

Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma

Blood (2023) 142 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2023-183011

Published: 2023

Journal Articles

Full Body Screening Computed Tomography Prior to Allogeneic Hematopoietic Stem Cell Transplantation: A Single Institution Experience from an Academic Center

Danielle McQuinn, Lauren Racki, Vaishalee P Kenkre, Matthew James Brunner, Zhubin J. Gahvari, Ryan J Mattison, Aric C. Hall, Kalyan Nadiminti

Blood (2023) 142 (Supplement 1): 378.

https://doi.org/10.1182/blood-2023-178878

Published: 2023

Journal Articles

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Blood (2022) 140 (Supplement 1): 10955–10957.

https://doi.org/10.1182/blood-2022-160431

Published: 2022

Journal Articles

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Jacob D. Soumerai, Catherine S. Diefenbach, Felipe Samaniego, Abhijeet Kumar, Michaela L. Tsai, Adam S. Asch, Deepa Jagadeesh, Vaishalee P. Kenkre, Izidore S. Lossos, Huda Salman, Farrukh T. Awan, Lu Miao, Richard G. Ghalie, Andrew D. Zelenetz

Blood (2022) 140 (Supplement 1): 189–191.

https://doi.org/10.1182/blood-2022-157563

Published: 2022

Journal Articles

Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy

Blood (2022) 140 (Supplement 1): 375–377.

https://doi.org/10.1182/blood-2022-163438

Published: 2022

Journal Articles

Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy

Blood (2022) 140 (Supplement 1): 2416–2418.

https://doi.org/10.1182/blood-2022-163822

Published: 2022

Journal Articles

Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 884.

https://doi.org/10.1182/blood-2021-147433

Published: 2021

Journal Articles

Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant

Blood (2021) 138 (Supplement 1): 878.

https://doi.org/10.1182/blood-2021-149880

Published: 2021

Journal Articles

Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices

Blood (2021) 138 (Supplement 1): 532.

https://doi.org/10.1182/blood-2021-147033

Published: 2021

Journal Articles

Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Veronika Bachanova, Livia Hegerova, Qing Cao, Murali Janakiram, Joseph Maakaron, Sabarish Ayyappan, Daniel J. Weisdorf, Jaroslav Zak, Umar Farooq, Vaishalee P. Kenkre

Blood (2021) 138 (Supplement 1): 230.

https://doi.org/10.1182/blood-2021-149675

Published: 2021

Journal Articles

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Andrew M. Evens, Alexey Danilov, Deepa Jagadeesh, Amy Sperling, Seo-Hyun Kim, Ryan Vaca, Catherine Wei, Daniel Rector, Suchitra Sundaram, Nishitha Reddy, Yong Lin, Umar Farooq, Christopher D'Angelo, David A. Bond, Stephanie Berg, Michael C. Churnetski, Amandeep Godara, Nadia Khan, Yun Kyong Choi, Maryam Yazdy, Emma Rabinovich, Gaurav Varma, Reem Karmali, Agrima Mian, Malvi Savani, Madelyn Burkart, Peter Martin, Albert Ren, Ayushi Chauhan, Catherine Diefenbach, Allandria Straker-Edwards, Andreas K. Klein, Kristie A. Blum, Kirsten Marie Boughan, Scott E. Smith, Brad M. Haverkos, Victor M. Orellana-Noia, Vaishalee P. Kenkre, Adam Zayac, Jeremy Ramdial, Seth M. Maliske, Narendranath Epperla, Parameswaran Venugopal, Tatyana A. Feldman, Stephen D. Smith, Andrzej Stadnik, Kevin A. David, Seema Naik, Izidore S. Lossos, Matthew A. Lunning, Paolo Caimi, Manali Kamdar, Neil Palmisiano, Veronika Bachanova, Craig A. Portell, Tycel Phillips, Adam J. Olszewski, Juan Pablo Alderuccio

Blood (2021) 137 (3): 374–386.

https://doi.org/10.1182/blood.2020006926

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis

Juan Pablo Alderuccio, MD, Adam J Olszewski, MD, Andrew M. Evens, DO,MMSc, Graham P. Collins, MD DPhil, Alexey Danilov, MD, Mark Bower, MD, Deepa Jagadeesh, MDMPH, Catherine Zhu, Amy Sperling, BS, Seo-Hyun Kim, MD, Ryan Vaca, MD, Catherine Wei, Suchitra Sundaram, MD, Nishitha Reddy, MD, Alessia Dalla Pria, MD, Christopher D'Angelo, MD, Umar Farooq, MD, David A. Bond, MD, Stephanie Berg, DO, Michael C. Churnetski, Amandeep Godara, MD, Nadia Khan, MD, Yun Kyong Choi, MD, Shireen Kassam, MBBS, FRCPath, PhD, Maryam Sarraf Yazdy, MD, Emma Rabinovich, MD, Frank Post, Gaurav Varma, MDMPH, Reem Karmali, MDMSc, Madelyn Burkart, MD, Peter Martin, FRCPC, MD MS, Albert Ren, Ayushi Chauhan, MBBS,MD, Catherine Diefenbach, MD, Allandria Straker-Edwards, MS, Andreas Klein, MD, Kristie A. Blum, MD, Kirsten M Boughan, DO, Agrima Mian, MBBS, MD, Bradley Haverkos, MD MPH, MS, Victor M. Orellana-Noia, MD, Vaishalee P. Kenkre, MD, Adam Zayac, MD, Seth M Maliske, MD, Narendranath Epperla, MDMS, Paolo F Caimi, MD, Scott E. Smith, MD PhD, Manali Kamdar, MD, Parameswaran Venugopal, MD, Tatyana A. Feldman, MD, Daniel Rector, Stephen D. Smith, MD, Andrzej Stadnik, MPH, BS, Craig A. Portell, MD, Yong Lin, PhD, Seema Naik, MD, Silvia Montoto, MD, Izidore S. Lossos, MD, Kate Cwynarski

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-136989

Published: 2020

Journal Articles

The Burkitt Lymphoma International Prognostic Index (BL-IPI)

Adam J Olszewski, MD, Lasse H. Jakobsen, PhD, Graham P. Collins, MD DPhil, Kate Cwynarski, Veronika Bachanova, MD PhD, Kristie A. Blum, MD, Kirsten M Boughan, DO, Mark Bower, MD, Alessia Dalla Pria, MD, Alexey Danilov, MD, Kevin A. David, MD, Catherine Diefenbach, MD, Fredrik Ellin, MD PhD, Narendranath Epperla, MDMS, Umar Farooq, MD, Tatyana A. Feldman, MD, Alina S. Gerrie, MD MPH, Deepa Jagadeesh, MDMPH, Manali Kamdar, MD MD, Reem Karmali, MDMSc, Shireen Kassam, MBBS, FRCPath, PhD, Vaishalee P. Kenkre, MD, Nadia Khan, MD, Andreas Klein, MD, Izidore S. Lossos, MD, Matthew A. Lunning, DO, FACP, Peter Martin, FRCPC, MD MS, Nicolas Martinex-Calle, Silvia Montoto, MD, Seema Naik, MD, Neil Palmisiano, MDMS, David Peace, MD, Elizabeth H Phillips, MBBS, BSc, Tycel J. Phillips, MD, Craig A. Portell, MD, Nishitha Reddy, MD, Anna Santarsieri, MBBS, Maryam Sarraf Yazdy, MD, Knut B. Smeland, Scott E. Smith, MD PhD, Stephen D. Smith, MD, Suchitra Sundaram, MD, Parameswaran Venugopal, MD, Adam Zayac, MD, Xiao-Yin Zhang, PhD, Catherine Zhu, Chan Yoon Cheah, MBBS, Tarec Christoffer El-Galaly, Andrew M. Evens, DO,MMSc

Blood (2020) 136 (Supplement 1): 46–49.

https://doi.org/10.1182/blood-2020-134985

Published: 2020

Journal Articles

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

Adam Zayac, MD, Andrew Matthew Evens, DO,MMSc, Andrzej Stadnik, MPH, BS, Stephen D. Smith, MD, Deepa Jagadeesh, MDMPH, Lori A. Leslie, MD, Catherine Wei, MD MA, Seo-Hyun Kim, MD, Seema Naik, MD, Suchitra Sundaram, MD, Nishitha Reddy, MD, Umar Farooq, MD, Vaishalee P. Kenkre, MD, Narendranath Epperla, MDMS, Kristie A. Blum, MD, Nadia Khan, MD, Daulath Singh, MD, Juan Pablo Alderuccio, MD, Amandeep Godara, MD, Maryam Yazdy, MD, Catherine Diefenbach, MD, Emma Rabinovich, MD, Gaurav Varma, MDMPH, Reem Karmali, MD, Yusra Shao, MD, Asaad Trabolsi, MD, Madelyn Burkart, MD, Peter Martin, FRCPC, MD MS, Sarah Stettner, Ayushi Chauhan, MBBS, Yun Kyong Choi, MD, Allandria Straker-Edwards, MS, Andreas Klein, MD, Michael C. Churnetski, Kirsten M Boughan, DO, Stephanie Berg, DO, Brad M. Haverkos, MDMPH,MS, Victor M. Orellana-Noia, MD, Christopher D'Angelo, MD, David A. Bond, MD, Seth M Maliske, MD, Ryan Vaca, MD, Gabriela Magarelli, APN, Amy Sperling, BS, Max J. Gordon, MD, Kevin A. David, MD, Paolo Caimi, MD, Manali Kamdar, MD, Craig A. Portell, MD, Parameswaran Venugopal, MD, Izidore S. Lossos, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 402.

https://doi.org/10.1182/blood-2019-122990

Published: 2019

Journal Articles

The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)

Andrew M. Evens, DO, MSc, Alexey Danilov, MD PhD, Deepa Jagadeesh, MDMPH, Amy Sperling, BS, Seo-Hyun Kim, MD, Ryan Vaca, MD, Catherine Wei, MD MA, Daniel Rector, Suchitra Sundaram, MD, Nishitha Reddy, MD, Yong Lin, PhD, Umar Farooq, MD, Christopher D'Angelo, MD, David A. Bond, MD, Stephanie Berg, DO, Michael C. Churnetski, Amandeep Godara, MD, Nadia Khan, MD, Yun Kyong Choi, MD, Maryam Yazdy, MD, Emma Rabinovich, MD, Gaurav Varma, MD MSPH, Reem Karmali, MD, Agrima Mian, MBBS, MD, Jeremy Ramdial, MD, Madelyn Burkart, MD, Peter Martin, FRCPC, MD MS, Albert Ren, Ayushi Chauhan, MBBS, Catherine Diefenbach, MD, Allandria Straker-Edwards, MS, Andreas Klein, MD, Kristie A. Blum, MD, Kirsten M Boughan, DO, Scott E. Smith, MD PhD, Brad M. Haverkos, MDMPH,MS, Victor M. Orellana-Noia, MD, Vaishalee P. Kenkre, MD, Adam Zayac, MD, Seth M Maliske, MD, Narendranath Epperla, MDMS, Parameswaran Venugopal, MD, Tatyana A. Feldman, MD, Stephen D. Smith, MD, Andrzej Stadnik, MPH, BS, Izidore S. Lossos, MD, Kevin A. David, MD, Seema Naik, MD, Paolo Caimi, MD, Manali Kamdar, MD, Craig A. Portell, MD, Adam J Olszewski, MD, Juan Pablo Alderuccio, MD

Blood (2019) 134 (Supplement_1): 397.

https://doi.org/10.1182/blood-2019-122971

Published: 2019

Journal Articles

Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis

Blood (2019) 134 (Supplement_1): 3982.

https://doi.org/10.1182/blood-2019-124783

Published: 2019

Journal Articles

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Julie E Chang, MD, Vaishalee P. Kenkre, MD, Christopher D. Fletcher, MD, Aric C. Hall, MD, Natalie Scott Callander, MD, Kyungmann Kim, PhD, Grace Yi Chen, Kaitlin Chambers

Blood (2019) 134 (Supplement_1): 5470.

https://doi.org/10.1182/blood-2019-124489

Published: 2019

NARROW

EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma

Minimal Residual Disease (MRD) Testing By Next Generation Sequencing (NGS) after Two Cycles (CY) of Non-Intensive Chemoimmunotherapy Is Predictive of Remission Duration and Need for Maintenance Therapy (MT) in Previously Untreated Mantle Cell Lymphoma (MCL): A Wisconsin Oncology Network Study

Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities

Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma

Full Body Screening Computed Tomography Prior to Allogeneic Hematopoietic Stem Cell Transplantation: A Single Institution Experience from an Academic Center

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy

Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy

Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy

Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant

Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices

Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis

The Burkitt Lymphoma International Prognostic Index (BL-IPI)

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis

The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)

Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only